Ex Vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small Interfering RNA

Christine Mannhalter¹

¹ Medical University Vienna, Vienna, Austria

Thromb Haemost 2020;120:1483.

Address for correspondence Christine Mannhalter, Medical University Vienna, Vienna 1090, Austria
(e-mail: christine.mannhalter@meduniwien.ac.at).

von Willebrand disease (VWD), the most common inherited bleeding disorder, is frequently caused by dominant-negative mutations in the gene coding for the multimeric protein von Willebrand factor (VWF).^{1,2} VWF is synthesized in endothelial cells and megakaryocytes and is coded by a 175-kb gene located on the short arm of chromosome 12. The gene carries several frequent single nucleotide polymorphisms (SNPs).³ In patients, different mutations in the gene have been reported, which can cause quantitative (type 1 and 3) or qualitative (type 2) defects.⁴ Treatment mostly relies on desmopressin, but substitution therapy with VWF is sometimes required. These therapies do not prevent mutant VWF being produced, and subsequent thrombocytopenia in the case of VWD type 2B or competition with normal VWF for platelet receptors can occur. In this issue of *Thrombosis and Haemostasis*, de Jong and coauthors⁵ present an ex vivo study in endothelial colony-forming cell clones (ECFCs) using allele-specific small interfering RNAs (siRNAs). In an earlier proof-of-principle study, the authors identified a siRNA, which targeted a heterozygous SNP located on the same allele as a type 2 mutation, which could successfully inhibit VWF expression in human embryonic kidney cells.⁶ Now they showed, in ECFCs isolated from a VWD type 2A patient, that this siRNA could knock down this mutant allele and improved the cellular phenotype in the patient's ECFCs. The results are very promising and should encourage future research to evaluate the efficiency and

specificity of allele-specific siRNAs, notably that allele-specific siRNAs can correct the bleeding phenotype in vivo and ultimately in patients.

Conflict of Interest

None declared.

References

- 1 James PD, Goodeve AC. von Willebrand disease. *Genet Med* 2011; 13(05):365–376
- 2 Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. *Blood* 2015;125(13):2019–2028
- 3 Hampshire DJ, Goodeve AC. The international society on thrombosis and haemostasis von Willebrand disease database: an update. *Semin Thromb Hemost* 2011;37(05):470–479
- 4 de Jong A, Eikenboom J. Von Willebrand disease mutation spectrum and associated mutation mechanisms. *Thromb Res* 2017; 159:65–75
- 5 de Jong A, Dirven RJ, Boender J, et al. Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-Interfering RNA. *Thromb Haemost* 2020;120 (11):1569–1579
- 6 de Jong A, Dirven RJ, Oud JA, Tio D, van Vlijmen BJM, Eikenboom J. Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor. *J Thromb Haemost* 2018;16(07):1357–1368

received
September 2, 2020
accepted
September 2, 2020

© 2020 Georg Thieme Verlag KG
Stuttgart · New York

DOI <https://doi.org/10.1055/s-0040-1718412>.
ISSN 0340-6245.